• Nuvalent flagged upcoming ASCO 2026 presentations of pivotal trial results for neladalkib in previously treated advanced ALK-positive non-small cell lung cancer, with an oral presentation scheduled for May 29.
• The readout supported a recent FDA New Drug Application submission, pointing to broad anti-tumor activity that included responses in the brain, with tolerability described as consistent with the drug’s selective design.
• ASCO will also feature a first look at preliminary ARROS-1 data for zidesamtinib in ROS1-positive solid tumors outside lung cancer, presented as a poster on May 30.
• The early dataset showed responses across a range of tumor types in both TKI-naïve and previously treated patients, with treatment generally tolerated and limited dose modification.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605211723PR_NEWS_USPR_____NE65791) on May 21, 2026, and is solely responsible for the information contained therein.